Oncology Market Forecast To 2013
|
|
- Janice Hicks
- 5 years ago
- Views:
Transcription
1 Oncology Market Forecast To 2013 How do you uncover the threats and opportunities that your oncology drug will face this year, next year and each year after that? Our new report answers your questions with the most comprehensive forecast of the competitive oncology marketplace ever created. We ve pulled together information over 130 drugs from today s blockbusters to tomorrow s most promising breakthrough molecules. Our analysis provides key decision-making information such as: what your competitors are aiming for what you need to do to beat them what market forces impact your Go/No-Go action which indications to target
2 Oncology Brand Marketing 2 Oncology Market Forecast to 2013 What do you need to know to make strategic and tactical decisions about your drug s success? Our research team analyzed sales performance, legal and regulatory changes, new product launches and recent changes in research strategy. We also studied likely trends, critical factors and hidden pitfalls for the next decade. No other resource gives you so much bedrock information on which to base your decision-making. What factors are you already looking at and what else do you need to be aware of? Key oncology trends are easy to follow in the headlines. But what s driving those trends? And what hidden factors are already shifting your competitors goals and strategy? This report looks at all the data to highlight what your team must do to be successful in and beyond Park Forty Plaza, Suite 440 Durham, NC Copyright CO 2008 Cutting Edge Information
3 Oncology Brand Marketing 3 Oncology Market Forecast to 2013 The report contains marketing analysis of over 130 drugs in a dozen drug classes and adjunct treatments including: What s currently approved and what are the upcoming new indications? What novel products are in development and what impact will they have on the market? What are the strategic market growth drivers? How are epidemiology and disease information impacting market size? What are the U.S. and global outlooks for current and future leaders? What are the major market events, such as competitors new launches, that your team must be aware of? What new research strategies will change the direction of key companies pipelines? With this level of comprehensive analysis, your team doesn t have to guess when making decisions about how to fund and prioritize products and franchises. You will have everything you need to make good decisions today Park Forty Plaza, Suite 440 Durham, NC Copyright CO 2008 Cutting Edge Information
4 Oncology Brand Marketing 4 Oncology Market Forecast to 2013 Selected Table of Contents The report is structured for easy access to the oncology product data you need. Chapter 1: Drug Class Analysis Antineoplastics (79) Alkylating Agents (9) Antimetabolites (8) Antimitotics (11) Cytotoxic Antibiotics (5) Hormones (10) Tyrosine Kinase Inhibitors (20) Monoclonal Antibodies (16) Immunostimulants (9) Other Cancer Treatments (32) Adjunct Treatments (16) 1000 Park Forty Plaza, Suite 440 Durham, NC Copyright CO 2008 Cutting Edge Information
5 Oncology Brand Marketing 5 Oncology Market Forecast to 2013 Selected Table of Contents The report is structured for easy access to the oncology product data you need. Chapter 2: Cancer Indication Market Analysis Breast Cancer Colorectal Cancer Leukemia Lung Cancer Prostate Cancer Chapter 3: Company Profiles Amgen AstraZeneca BristolMyersSquibb Celgene Eli Lilly GlaxoSmithKline ImClone Johnson & Johnson Merck Novartis Pfizer Roche Sanofi-Aventis Schering-Plough 1000 Park Forty Plaza, Suite 440 Durham, NC Copyright CO 2008 Cutting Edge Information
6 1CHAPTER 1: Cancer brand profiles
7 CHAPTER Cancer Brand Profiles Cutting Edge Information analyzed the market strengths and opportunities of 136 oncology brands and adjunct therapies. The following profiles include information about drugs competitive and strategic positions, market opportunities and growth, and patent or litigation information, when applicable. The brand profiles are organized by the following drug classes: Antineoplastics o Alkylating agents o Antimetabolites o Antimitotics o Antibiotics o Hormone therapies o Tyrosine kinase inhibitors o Monoclonal antibodies Immunostimulants Other cancer treatments Adjunct therapies
8 Alkeran (melphalan) Manufacturer/Partners: Celgene and GlaxoSmithKline Drug Class: alkylating agent Delivery Mechanisms: injectable; oral Line of Treatment: third-line, palliative therapy ONCOLOGY BRAND PROFILES - 8 Development Table Company Indication Description Development Stage Celgene Corporation Myeloma Multiple Myeloma Approved Competitive and Strategic Positioning GlaxoSmithKline drug Alkeran was first approved in the US in July In April 2003, Celgene entered into a three-year licensing agreement with GlaxoSmithKline to distribute Alkeran under the Celgene label in the US. The agreement has been extended through March 31, The deal is automatically extendable for one year periods, unless either party alerts the other at least one year before the renewal date that it elects not to extend the agreement. Alkeran is an important addition for Celgene because its palliative treatment of multiple myeloma coheres with Celgene s incredibly successful second-line multiple myeloma treatment, Revlimid. It can also be used in combination with Celgene s Thalomid for newly diagnosed cases of multiple myeloma. Additionally, it is used as a palliative treatment for carcinoma of the ovary. The combination of Revlimid, Thalomid and Alkeran has proven rather successful for Celgene. In 2007, Alkeran achieved sales of $73 million, complementing the $677 million Revlimid generated in the US market. Clinical trials continue to strengthen Alkeran s profile, as the treatment proves effective as a palliative option for a range of hematological diseases. Alkeran is also adaptable and convenient it is available in both intravenous and tablet forms. Patients who cannot take the tablet form can instead have Alkeran administered via injection, Alkeran Materiality Copyright Cutting Edge Information
9 ONCOLOGY BRAND PROFILES - 9 Market Opportunities and Growth With Alkeran sales projected to remain in the $70 million range for the next five years, the agreement between GSK and Celgene has proved profitable for both. Sales of Alkeran are not projected to fall off because of Alkeran s ability to be combined with other treatments. Because of the treatment s complementary attributes to Revlimid even though Alkeran s US patent expires in November 2008 Celgene will most likely try to maintain this agreement for a number of years. In addition, GSK and Celgene still hold the option to sue for the 30-month stay if any company decides to try to produce a generic. No competition appears to be readying for a generic, most likely due to Alkeran s limited revenue in the US. GSK holds patents for Alkeran in Europe. Patent Information Patent # Expiration Date /18/2008 Generic Information Manufacturer Generics Available No generics available Market Exclusivity Reason Expiration Date No data available Patent and Litigation Information The US patent for Alkeran expires November 18, No patent litigation is pending at this time. Alkeran Sales: (in millions) Copyright Cutting Edge Information
10 3 CHAPTER 3: oncology drug manufacturer Profiles
11 CHAPTER3 Oncology Drug Manufacturer Profiles The following oncology drug manufacturer profiles provide insight into companyspecific strategies for their cancer drug pipelines. Cutting Edge Information s analysts compiled research for 14 pharmaceutical and biotechnology drug manufacturers. These companies have either established oncology franchises or exciting development pipelines for new cancer compounds. Profiles companies include: Amgen AstraZeneca Celgene Bristol-Myers Squibb Eli Lilly GlaxoSmithKline ImClone Johnson & Johnson Merck Novartis Pfizer Sanofi-Aventis Schering-Plough Each company profile provides information about the company s competitive and strategic positioning, as well as the company s performance and oncology development pipeline. The profiles are designed to inform readers about current trends in companies strategies toward the oncology market.
12 ONCOLOGY MANUFACTURER PROFILES 12 AstraZeneca Oncology Ranking, 2007: #5 Oncology Ranking, 2013: #11 (Projected) Industry Ranking, 2007: #5 Oncology Blockbusters: 2 (Arimidex, Casodex) Oncology Products on Market: 4 Oncology Products in Phase III Trials: 4 AstraZeneca Oncology Market Share Competitive and Strategic Positioning AstraZeneca is a top 10 pharmaceutical company and relied on oncology drugs for 12% of its revenue in Arimidex and Zoladex are AstraZeneca s largest oncology drugs, together expected to grow to over $3 billion in sales by Both are indicated for breast cancer, as is Faslodex. Nolvadex was also indicated for breast cancer but sales were discontinued in 2006 due to declining sales, as its patent had expired. Iressa, a once promising lung cancer drug, suffered a devastating setback when the FDA restricted sales in 2005 to patients who had already received the drug. Iressa seemed so promising in earlystage trials that it was approved prior to completing trials. Upon the completion of trials, however, the results were very disappointing, and the FDA changed the label to prevent new prescriptions. While Iressa still has hundreds of millions of dollars of sales overseas, Genentech s Tarveca has taken over the anti-egfr market. AstraZeneca hopes to reclaim those sales with Zactima, an anti-egfr drug in Phase III trials. Recentin and ZD4054, two other AstraZeneca drugs in trials for brain and prostate cancer respectively, are projected to be approved in and have sales of nearly $300 million each by 2014.
13 Company Performance Strengths: A top 10 pharma company, AstraZeneca can devote resources to promising drugs as needed. Zactima s dual mechanism of action could potentially steal sales from both Tarceva and Avastin if it proves superior to those drugs in efficacy. Zactima is also in Phase II development for many different indications, which could boost sales dramatically as the drug matures. Growth Areas: Recentin suffered a setback in recent trials results for the NSCLC indication, and its anticipated approval date was pushed back to 2010 as AstraZeneca focuses on the colorectal cancer indication instead. ZD4054, is currently only being tested for prostate cancer. Additional indications, if even possible, would take years after approval to earn. AstraZeneca is currently heavily reliant on breast cancer drugs in its oncology portfolio, and if new drug treatments change the breast cancer market, AstraZeneca s oncology portfolio will suffer. Competition: Arimidex is the best-selling aromatase inhibitor on the market. This first-line class of breast cancer drugs is projected to further increase its market share in the coming years. Casodex will be facing generic competition later this year, which will reduce its sales by over 50% in the next two years. After the failure of Iressa in the US market, AstraZeneca hopes to take reclaim lost market share from Tarceva with its Phase III anti-egfr drug, Zactima. ONCOLOGY MANUFACTURER PROFILES 13 AstraZeneca s 2007 Oncology Revenue AstraZeneca s 2013 Oncology Revenue
14 Products Arimidex has been FDA approved since December 1995 and has three hormone receptor-positive breast cancer indications for postmenopausal women. In 2007, final results from a study comparing Arimidex to tamoxifen therapy for breast cancer were announced Arimidex beat tamoxifen in preventing the recurrence of breast cancer after five years of therapy. As a result, sales are expected to grow from the current $1.7 billion in annual sales to over $2 billion in Sales will then face a slow decline as a result of patent expirations. Casodex is a prostate cancer treatment that has been on the market for over a decade. Casodex reached its peak global sales in 2007, when it reaped about $1.3 billion worldwide. However, the brand s sales are expected to be chopped in half in the next couple of years after its patent expires in October of Faslodex is an estrogen receptor downregulator indicated for treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression. The highly restrictive indication for Faslodex also restricts its market share; in 2007 it had less than $200 million in sales. The primary growth potential for Faslodex is in additional cancer indications, which are currently in phase II studies. Its use in cancer is limited to estrogenreceptor positive cancer cells, and it is currently being tested in ovarian, prostate and lung cancers. Iressa is a selective EGFR inhibitor that was FDA approved in 2003 for third-line treatment of non small cell lung cancer Iressa subsequently failed to show a survival benefit, and the FDA restricted access to the drug and allowed no new prescriptions. While Iressa has no future in the US or the EU for NSCLC, it is approved in many other countries, and continues to generate between $200 and $300 million in revenue for AstraZeneca. Nolvadex, initially approved 1973, is a highly popular breast cancer drug that is just recently being supplanted by the aromatase inhibitors. After expiration of the last of its patents in the early 2000 s, generic competition has eaten away at Nolvadex s sales. AstraZeneca discontinued sales of Nolvadex in the US in June of 2006, due to declining sales and the fact that generic versions of the drug are now widely available. Zoladex is the second-largest selling LHRH agonist, for use in hormone-responsive cancers in the prostate and breast. It was first approved by the FDA in 1989 and its US patent has since expired. Worldwide sales continue to make this a blockbuster drug, and patents will not expire for years in many of the over 100 markets it serves. Analysts project a slow decline in global sales from the current $1 billion to $700 million by ONCOLOGY MANUFACTURER PROFILES 14
15 Recentin is an experimental treatment for non-small cell lung cancer and colorectal cancer. AstraZeneca anticipates filing an NDA for Recentin in In February of 2008, AstraZeneca announced the company will not move forward into Phase III trials to evaluate Recentin for non-small cell lung cancer, but is moving forward in the indication of colorectal cancer. According to early predictions, the drug will launch sometime in 2010 with $50 million in sales, and sales will peak at $281 million sometime after Zactima is a VEGFR and EGFR inhibitor currently in Phase III trials for lung cancer. After positive Phase II results, AstraZeneca started their first Phase III trial in 2005, and has subsequently added three more. The FDA in 2005 also granted Orphan status to Zactima for its potential use in thyroid cancer. AstraZeneca plans to file for submission in 2008, and analysts project approval in 2009 and growth to nearly $300 million in sales by ZD4054 is an endothelin A receptor antagonist currently in Phase III trials for hormone-refractory prostate cancer. AstraZeneca has been aggressively moving this drug towards FDA approval for prostate cancer indications, and has not initiated trials for any other indication. Analysts are projecting approval for this drug in 2010, and worldwide sales growth from $50 million to nearly $300 million by ONCOLOGY BRAND PROFILES 15
16 Oncology Brand Marketing 16 Oncology Market Forecast to 2013 Start using the report today. We designed this report to give every oncology product team the information they need to be as effective as possible. Whether you re launching your company s first cancer drug or adding to a thriving portfolio, you need to know your strengths and weaknesses. To order your copy today, call Adam Bianchi at or write to adam_bianchi@ceireports.com. Quick Summary Chapter 1 Analysis of Cancer Drugs by Classes Chapter 2 Analysis of Oncology Indications Chapter 3 Analysis of Top Companies Oncology Portfolios REPORT LENGTH 350+ pages in PDF or hard copy format METRICS AND CHARTS 1,000+ metrics All leading oncology companies analyzed 1000 Park Forty Plaza, Suite 440 Durham, NC Copyright CO 2008 Cutting Edge Information
Oncology Market Opportunities, Strategies, and Forecasts, 2006 to Oncology. Picture by Susie Eustis MOUNTAINS OF OPPORTUNITY
Oncology Market Opportunities, Strategies, and Forecasts, 2006 to 2012 Oncology Picture by Susie Eustis MOUNTAINS OF OPPORTUNITY WinterGreen Research, Inc. Lexington, Massachusetts www.wintergreenresearch.com
More informationUS pharmaceutical market: trends, issues, forecast. Doug Long Vice President Industry Relations IMS Health
US pharmaceutical market: trends, issues, forecast Doug Long Vice President Industry Relations IMS Health 2006 Strategic management review The World Pharmaceutical Market All reproduction rights, quotations,
More informationOncology Pipeline Analytics
Oncology Pipeline Analytics Trials, Drug Classes, Indications, Correlations and Strategies Report Brochure O n c o l o g y P i p e l i n e A n a l y t i c s Greystone Research Associates is pleased to
More informationJohn Ansell President, John Ansell Consultancy Thame, UK
Rutgers University Monday 29 September 2014 Co Eli Lilly Bristol-Myers Squibb Novo Nordisk Pfizer GlaxoSmithKline Takeda Sanofi Novartis AstraZeneca Roche Otsuka Johnson & Johnson Otsuka Abbott Teva 1
More informationGastric Cancer Drug Discoveries
Gastric Cancer Drug Discoveries what the future holds March 2011 World Leaders in Health Industry Analysis Market Analysis Market Analysis There is room for considerable change in the gastric cancer market
More informationCrisis Investing: Profits From a Diabetes Drug About to Get Approved Crisis Investing: Profits From a Diabetes Drug About to Get Approved
Crisis Investing: Profits From a Diabetes Drug About to Get Approved A Special Research Report from Bret Jensen's Biotech Gems Lexicon Pharmaceuticals (Nasdaq: LXRX): tackling one of America s biggest
More informationExecutive Summary. Reproduction prohibited v
Kinases are a large family of proteins that have now become firmly established as a major class of drug targets for the pharmaceutical industry. The sequencing of the Human Genome has led to the identification
More informationFor personal use only
Targeted DEP shows sustained superior performance in ovarian cancer model Melbourne, Australia; 2 February 2016: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced the final results of the preclinical
More informationBayer and Loxo Oncology to develop and commercialize two novel oncology therapies selectively targeting genetic drivers of cancer
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies
More informationTHYROID HORMONE THERAPY TABLE 21 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR FIGURE 4 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THIS STUDY... 1 INTENDED AUDIENCE... 1 SCOPE OF REPORT... 2 METHODOLOGY... 2 INFORMATION SOURCES... 2 ANALYST S CREDENTIALS...
More informationBRIC DIABETES DRUGS MARKET
BRIC DIABETES DRUGS MARKET R e p o r t D e s c r i p t i o n T a b l e o f C o n t e n t s L i s t o f T a b l e s S a m p l e T a b l e s R e l a t e d R e p o r t s A b o u t M a r k e t s a n d M a
More informationDatamonitor Healthcare Pharma intelligence. GlaxoSmithKline: Company Analysis
Datamonitor Healthcare Pharma intelligence GlaxoSmithKline: Company Analysis OVERVIEW Latest Earnings Review Q2 2018 [27 July 2018] Click to view analysis Latest Forecast Update Q2 2018 [2 August 2018]
More informationOncology Therapeutics Market in India to 2018
Oncology Therapeutics Market in India to 2018 Introduction of Market-Based Pricing to Fuel Price Wars and Intense Competition Among Domestic and Multinational Players GBI Research Report Guidance GBI Research
More information27 th Annual J.P. Morgan Healthcare Conference. January 13, 2009
27 th Annual J.P. Morgan Healthcare Conference January 13, 2009 1 Forward Looking Statements This presentation and any subsequent Q&A may contain forward-looking statements, including with respect to:»
More informationJP Morgan Healthcare Conference
JP Morgan Healthcare Conference Lamberto Andreotti Chief Executive Officer January 14, 2014 Forward-Looking Information During this meeting, we will make statements about the Company s future plans and
More informationREFERENCE CODE GDHC1174DFR PUBLICATION DATE M AY 2013
REFERENCE CODE GDHC1174DFR PUBLICATION DATE M AY 2013 XELJANZ (PSORIASIS) - Executive Summary Table below presents key metrics for Xeljanz (tofacitinib) in seven of the nine major pharmaceutical markets
More informationCase 2:09-cv FSH-PS Document 1-3 Filed 08/24/2009 Page 1 of 5. Exhibit B
Case 2:09-cv-04329-FSH-PS Document 1-3 Filed 08/24/2009 Page 1 of 5 Exhibit B Case 2:09-cv-04329-FSH-PS Document 1-3 Filed 08/24/2009 Page 2 of 5 TO OUR FELLOW SHAREHOLDERS: In 2001 we made significant
More informationInfinity Highlights Promising Preclinical Hedgehog Data and Announces First Quarter Financial Results
Infinity Highlights Promising Preclinical Hedgehog Data and Announces First Quarter Financial Results Heat Shock Protein 90 Program Continues to Advance Toward Potential Registration Trial CAMBRIDGE, Mass.,
More informationBank of America Merrill Lynch 2016 Health Care Conference
Bank of America Merrill Lynch 2016 Health Care Conference Dr. Steven Stein Chief Medical Officer David Gryska Chief Financial Officer May 11, 2016 Forward Looking Statements Except for the historical information
More informationHALOZYME REPORTS SECOND QUARTER 2018 RESULTS
Contacts: Robert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 robert.uhl@westwicke.com Laurie Stelzer 858-704-8222 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME REPORTS SECOND QUARTER
More informationREFERENCE CODE GDHC1170DFR PUBLICATION DATE M AY 2013
REFERENCE CODE GDHC1170DFR PUBLICATION DATE M AY 2013 BRODALUMAB (PSORIASIS) - Executive Summary Table below presents key metrics for brodalumab in seven of the nine major pharmaceutical markets covered
More informationDendrimer-Oxaliplatin shows better anti-cancer efficacy and less toxicity
Dendrimer-Oxaliplatin shows better anti-cancer efficacy and less toxicity Melbourne, Australia; Wednesday 11 September 2013: Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced it had achieved
More informationRegorafenib from Bayer Submitted to Health Authorities Seeking Approval in Second-Line Treatment of Liver Cancer
News Release Not intended for U.S. and UK Media Bayer AG Communications, Government Relations & Corporate Brand 51368 Leverkusen Germany Tel. +49 214 30-0 www.news.bayer.com Regorafenib from Bayer Submitted
More information08:FORECAST. The View From the Office: How Community Oncologists See 2008 By Peter Carlin and Don Stark of Market Strategies International
08:FORECAST A Survey of Oncologists Provides Insight Into the Coming Year The View From the Office: How Community Oncologists See 2008 By Peter Carlin and Don Stark of Market Strategies International While
More informationGASTRIC CANCER TESTING, TREATMENT AND PREVENTION: TECHNOLOGIES AND GLOBAL MARKETS. HLC174A October Usha Nagavarapu Project Analyst
GASTRIC CANCER TESTING, TREATMENT AND PREVENTION: TECHNOLOGIES AND GLOBAL MARKETS HLC174A October 2015 Usha Nagavarapu Project Analyst ISBN: 1-62296-167-6 BCC Research 49 Walnut Park, Building 2 Wellesley,
More informationREFERENCE CODE GDHC294DFR PUBLICATION DATE NOVEMBER 2013 PROTOPIC (ATOPIC DERMATITIS) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC294DFR PUBLICATION DATE NOVEMBER 2013 PROTOPIC (ATOPIC DERMATITIS) Executive Summary The below mentioned table presents key metrics for Protopic in the nine major pharmaceutical markets
More informationDARA Reports Year-End 2012 Financial Results
April 1, 2013 DARA Reports Year-End 2012 Financial Results Company Provides a Commercial Portfolio and Development Pipeline Business Update RALEIGH, NC -- (MARKETWIRE) -- 04/01/13 -- DARA BioSciences,
More informationDS-8201 Strategic Collaboration
DS-8201 Strategic Collaboration DAIICHI SANKYO CO., LTD George Nakayama Chairman and CEO March 29, 2019 Forward-Looking Statements Management strategies and plans, financial forecasts, future projections
More informationCustom Intelligence. Alzheimer s Disease Landscape Summary
Custom Intelligence Alzheimer s Disease Landscape Summary Prepared August 21 Alzheimer s Disease Landscape: Executive Summary Current standard of care in Alzheimer s Disease (AD) consists of symptomatic
More informationNektar Investor & Analyst Call. Nektar & z Bristol-Myers Squibb Collaboration. February 14, 2018
Nektar Investor & Analyst Call Nektar & z Bristol-Myers Squibb Collaboration February 14, 2018 This presentation includes forward-looking statements regarding Nektar s proprietary drug candidates, the
More informationBuilding a Premier Oncology Biotech
Corporate Presentation Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO January 2019 Forward-Looking Statements All of the statements in this presentation that are not statements
More informationOncology Therapeutics without Compromise APRIL 2011
Oncology Therapeutics without Compromise APRIL 2011 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties, including among other
More informationINCRETIN-BASED DRUGS: MARKETS FOR DIABETES THERAPIES AND DEVELOPING TREATMENTS
INCRETIN-BASED DRUGS: MARKETS FOR DIABETES THERAPIES AND DEVELOPING TREATMENTS PHM162A February 2015 Kim Lawson Project Analyst ISBN: 1-62296-047-5 BCC Research 49 Walnut Park, Building 2 Wellesley, MA
More informationTHERAPIES AND DIAGNOSTICS FOR OVARIAN CANCER. HLC143A June Usha Nagavarapu Project Analyst ISBN: X
THERAPIES AND DIAGNOSTICS FOR OVARIAN CANCER HLC143A June 2013 Usha Nagavarapu Project Analyst ISBN: 1-56965-431-X BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 866-285-7215, 781-489-7301
More informationCorcept Therapeutics, Inc.
March 20, 2015 Corcept Therapeutics, Inc. NEUTRAL Current Recommendation Prior Recommendation Outperform Date of Last Change 03/20/2015 Current Price (03/19/15) $5.85 Target Price $6.25 (CORT-NASDAQ) SUMMARY
More informationMedivation, Inc. (MDVN-NASDAQ)
March 19, 2015 Medivation, Inc. (MDVN-NASDAQ) NEUTRAL Current Recommendation Prior Recommendation Outperform Date of Last Change 03/25/2014 Current Price (03/18/15) $132.19 Target Price $139.00 SUMMARY
More informationREFERENCE CODE GDHC1114CFR PUBLICATION DATE M AY 2013
REFERENCE CODE GDHC1114CFR PUBLICATION DATE M AY 2013 PSORIASIS - Psoriasis - India Drug Forecast and Market Analysis to Executive Summary Sales for Psoriasis in India 2012 We estimate the 2012 PsO drug
More informationYour Contacts. EMA ODD is an important regulatory milestone for avelumab in metastatic Merkel cell carcinoma (MCC)
Your Contacts News Release Merck KGaA, Darmstadt, Germany Media: Gangolf Schrimpf +49 6151 72 9591 Investor Relations: +49 6151 72 3321 Pfizer Inc., New York, USA Media: Lisa O Neill +44 1737 331536 Investor
More informationPhotocure ASA Executing the Strategy
Photocure ASA Executing the Strategy NOVEMBER 2012 ERIK DAHL, CFO KATHLEEN DEARDORFF, COO Disclaimer The information included in this Presentation contains certain forward-looking statements that address
More informationBuilding a Premier Oncology Biotech
Corporate Presentation Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO February 2019 Forward-Looking Statements All of the statements in this presentation that are not statements
More informationGlobal Skin Cancer Diagnosis and Therapeutics Market Research and Forecast
Report Information More information from: https://www.wiseguyreports.com/reports/3186925-global-skin-cancer-diagnosis-and-therapeuticsmarket-research Global Skin Cancer Diagnosis and Therapeutics Market
More informationAVEO and Astellas Report Final Overall Survival Results from TIVO-1
AVEO and Astellas Report Final Overall Survival Results from TIVO-1 - Median Overall Survival of 28.8 Months Reported for Tivozanib in Patients with Advanced Kidney Cancer - CAMBRIDGE, Mass. and TOKYO,
More informationGlobal Epilepsy Market: Industry Analysis & Outlook
Industry Research by Koncept Analytics Global Epilepsy Market: Industry Analysis & Outlook ----------------------------------------- February 2017 1 Executive Summary Epilepsy is a group of neurological
More informationRestoration. JDRF is turning Type One into Type None. attack so the newly restored beta cell function is protected.
Restoration JDRF is turning Type One into Type None Type 1 diabetes (T1D) is an extraordinarily complex disease. Finding the cure a short-term clinical intervention, with minimal side effects, after which
More informationREFERENCE CODE GDHC295DFR PUBLICATION DATE NOVEMBER 2013 ELIDEL (ATOPIC DERMATITIS) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC295DFR PUBLICATION DATE NOVEMBER 2013 ELIDEL (ATOPIC DERMATITIS) Executive Summary The below mentioned table presents key metrics for Elidel in the major pharmaceutical markets: the
More informationPresentation to AGM 9 November Deborah Rathjen CEO & Managing Director
Presentation to AGM 9 November 2011 Deborah Rathjen CEO & Managing Director Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward looking" statements within the
More informationManaging out-licensing collaborations: a big pharma perspective
Managing out-licensing collaborations: a big pharma perspective Arne Wörn, PhD, Head Alliance Management IID European PLG Conference, Copenhagen, Sept. 5-6 These materials contain certain forward-looking
More informationPositioned for Growth
Positioned for Growth Annual Shareholders Meeting July 21, 2016 Paris Panayiotopoulos President and Chief Executive Officer David Sachs Non small cell lung cancer ARIAD clinical trial patient This presentation
More informationREFERENCE CODE GDHC296DFR PUBLICATION DATE NOVEMBER 2013 DUPILUMAB (ATOPIC DERMATITIS) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC296DFR PUBLICATION DATE NOVEMBER 2013 DUPILUMAB (ATOPIC DERMATITIS) Executive Summary The below mentioned table presents key metrics for Dupilumab in the nine major pharmaceutical markets
More informationPharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2024 PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2024 BioPortfolio has been marketing business and market research
More informationPrevention and Treatment of Prostate Cancer: Technologies and Global Markets March Usha Nagavarapu. Report # PHM113B
Prevention and Treatment of Prostate Cancer: Technologies and Global Markets March 2017 Usha Nagavarapu Report # PHM113B Table of Contents Chapter 1 Introduction... 1 Introduction... 1 Study goals and
More informationREFERENCE CODE GDHC1013FPR PUBLICAT ION DATE AUGUST 2013 MENINGOCOCCAL VACCINES - CURRENT AND FUTURE PLAYERS
REFERENCE CODE GDHC1013FPR PUBLICAT ION DATE AUGUST 2013 MENINGOCOCCAL VACCINES - Executive Summary Meningococcal Vaccines: Key Metrics in the Nine Major Pharmaceutical Markets 2012 Epidemiology Targeted
More informationVascular Endothelial Growth Factor Inhibitor Market
May 2017 Report Id : REP-GB-3292 Status : Ongoing Category : Healthcare, Pharmaceuticals & Medical Devices 2015 Future Market Insights, All Rights Reserved About Future Market Insights Future Market Insights
More informationJefferies Global Life Sciences Conference June 2010
Jefferies Global Life Sciences Conference June 2010 Cautionary Statement This presentation contains "forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act
More informationREFERENCE CODE GDHC465DFR PUBLICAT ION DATE SEPTEMBER 2014 KADCYLA (HER2-POSITIVE BREAST CANCER) - FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC465DFR PUBLICAT ION DATE SEPTEMBER 2014 KADCYLA (HER2-POSITIVE BREAST CANCER) - Executive Summary The table below presents the key metrics for Kadcyla for human epidermal growth factor
More informationActemra (Rheumatoid Arthritis)
Actemra (Rheumatoid Arthritis) Forecast and Market Analysis GDHC1007DFR / Published November 2012 Executive Summary Actemra: Key Metrics in Rheumatoid Arthritis Markets 2012 Actemra Sales Total 7 MM $355m
More informationCytomegalovirus (CMV) Infections - Pipeline Assessment and Market Forecasts to 2019
Reference Code: GDHC504PRT Publication Date: January 2013 Cytomegalovirus Infections: Key Metrics in Seven Major Pharmaceutical Markets 2012 Epidemiology* Prevalent population (CMV prevalent cases in general
More informationRoche Diagnostics Daniel O Day COO Roche Diagnostics. Société Générale - The Premium Review Conference, Paris December 2, 2011
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates,
More informationJefferies 2016 Healthcare Conference. Reid Huber, PhD Chief Scientific Officer
Jefferies 2016 Healthcare Conference Reid Huber, PhD Chief Scientific Officer June 8, 2016 Forward-looking Statements Except for the historical information set forth herein, the matters set forth in this
More informationREFERENCE CODE GDHC109PIDR PUBLICAT ION DATE MAY 2015 FIBROMYALGIA GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC109PIDR PUBLICAT ION DATE MAY 2015 FIBROMYALGIA GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023 Executive Summary Fibromyalgia: Key Metrics in Seven Major Pharmaceutical Markets, 2013
More informationMEDICINES FOR SMOKING CESSATION: GLOBAL MARKETS. PHM154A September Anand Gijare Project Analyst ISBN:
MEDICINES FOR SMOKING CESSATION: GLOBAL MARKETS PHM154A September 2013 Anand Gijare Project Analyst ISBN: 1-56965-544-8 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 866-285-7215, 781-489-7301
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer September 2013 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results
More informationOncology Drug Development
Oncology Drug Development Presentation to BioShares Biotech Summit 2018 Queenstown, NZ 27 July 2018 ASX: KZA NASDAQ: KZIA Twitter: @KaziaTx Oncology remains the largest and fastest-growing sector of the
More informationBuilding a Premier Oncology Biotech
Corporate Deck Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO November 2018 Forward-Looking Statements All of the statements in this presentation that are not statements of historical
More informationImmunocore and MedImmune announce new collaboration to conduct immuno-oncology combination trials in melanoma
PRESS RELEASE IMMUNOCORE LIMITED Immunocore and MedImmune announce new collaboration to conduct immuno-oncology combination trials in melanoma (Oxford, UK, 16 April 2015) Immunocore Limited, a world-leading
More informationREFERENCE CODE GDHC476DFR PUBLICAT ION DATE NOVEMBER 2014 CYRAMZA (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC476DFR PUBLICAT ION DATE NOVEMBER 2014 CYRAMZA (COLORECTAL CANCER) Executive Summary Table below presents the key metrics of Cyramza for colorectal cancer (CRC) in the eight major pharmaceutical
More informationIdenix Pharmaceuticals Building a Leading Antiviral Franchise. Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston
Idenix Pharmaceuticals Building a Leading Antiviral Franchise Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston Safe Harbor This presentation includes forward-looking statements
More informationAstraZeneca to Acquire Bristol- Myers Squibb Share of Global Diabetes Alliance. Becoming Global Leaders In Diabetes
AstraZeneca to Acquire Bristol- Myers Squibb Share of Global Diabetes Alliance Becoming Global Leaders In Diabetes 19th December 2013 Cautionary Statement Regarding Forward-Looking Statements In order,
More informationPancreatic Cancer Market Research Report- Global Forecast till 2023
Report Information More information from: https://www.marketresearchfuture.com/reports/1638 Pancreatic Cancer Market Research Report- Global Forecast till 2023 Report / Search Code: MRFR/HC/1107-HCRR Publish
More informationREFERENCE CODE GDHC472DFR PUBLICAT ION DATE NOVEM BER 2014 STIVARGA (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC472DFR PUBLICAT ION DATE NOVEM BER 2014 STIVARGA (COLORECTAL CANCER) Executive Summary Table below presents the key metrics for Stivarga for colorectal cancer (CRC) in the eight major
More informationScope and Methodology Size and Growth of the Market Issues and Trends Affecting the Rx-to-OTC Switches Market Leading Competitors
TABLE OF CONTENTS CHAPTER ONE: EXECUTIVE SUMMARY Scope and Methodology Size and Growth of the Market Issues and Trends Affecting the Rx-to-OTC Switches Market Leading Competitors CHAPTER TWO: INTRODUCTION
More information37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE
37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationSG Cowen 23rd Annual Health Care Conference March 18, Shire Pharmaceuticals Group plc
SG Cowen 23rd Annual Health Care Conference March 18, 2003 Shire Pharmaceuticals Group plc THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements included herein
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C Form 6-K
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month
More informationGlobal Strategic Partners Merck and Pfizer Finalize Agreement to Co-Promote XALKORI (crizotinib)
Merck Media: Markus Talanow +49 6151 72 7144 Investor Relations: +49 6151 72 3321 Pfizer Media: Sally Beatty +1 212 733 6566 Investor Relations: Ryan Crowe +1 212 733 8160 News Release April 7, 2015 Not
More informationMedia Contact: Ron Rogers Investor Contact: Scott Gleason (801) (801)
News Release Media Contact: Ron Rogers Investor Contact: Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Receives FDA Approval of BRACAnalysis CDx as Companion
More informationCiti Global Healthcare Conference
Citi Global Healthcare Conference Francis Cuss, MB BChir, FRCP Chief Scientific Officer February 24, 2014 1 Forward-Looking Information During this meeting, we will make statements about the Company s
More informationREFERENCE CODE GDHC1033FPR PUBLICAT ION DATE M ARCH 2014 PARKINSON S DISEASE - CURRENT AND FUTURE PLAYERS
REFERENCE CODE GDHC1033FPR PUBLICAT ION DATE M ARCH 2014 PARKINSON S DISEASE - CURRENT AND FUTURE PLAYERS Executive Summary Sales for Parkinson s Disease Market The Parkinson s disease market in the US,
More informationSAMPLE. Rencarex (Renal Cell Carcinoma)- Analysis and Forecasts to Reference Code: GDHC0004RCCDVR Publication Date: March 2012
Rencarex (Renal Cell Carcinoma)- Analysis and Forecasts to Reference Code: GDHC0004RCCDVR Publication Date: March 2012 The Renal Cell Carcinoma (RCC) Disease Therapeutics Market GlobalData s analysis suggests
More informationChina Oral Hypoglyceimic Agents (OHAs) Industry Report, Feb. 2011
China Oral Hypoglyceimic Agents (OHAs) Industry Report, 2010 Feb. 2011 This report Analyzes the status quo and prospect of Chinese OHAS Market. Related Products China Interventional Cardiovascular Device
More informationInvestor Presentation December The vision to see past tomorrow
Investor Presentation December 2011 The vision to see past tomorrow Safe Harbor Statement Certain statements contained herein are forward-looking statements (as such term is defined in the Private Securities
More informationGalvus US NDA Approvable - Overview
Galvus US NDA Approvable - Overview Galvus NDA filed with FDA Jan 2006 PDUFA action date extended by 3 months until February 26th 2007 Significant new clinical data added to NDA - Approximately 1000 patient
More informationChronic Myeloid Leukemia (CML)
Chronic Myeloid Leukemia (CML) Japan Drug Forecast and Market Analysis to 2022 GDHC1088CFR / Published April 2013 Executive Summary Sales for CML in Japan The Japan CML therapeutics market in the 7MM is
More informationONCOLOGY: WHEN EXPERTISE, EXPERIENCE AND DATA MATTER. KANTAR HEALTH ONCOLOGY SOLUTIONS: FOCUSED I DEDICATED I HERITAGE
CATALYSTS DRIVING SUCCESSFUL DECISIONS IN LIFE SCIENCES ONCOLOGY: WHEN EXPERTISE, EXPERIENCE AND DATA MATTER. KANTAR HEALTH ONCOLOGY SOLUTIONS: FOCUSED I DEDICATED I HERITAGE AT KANTAR HEALTH, ONCOLOGY
More informationIndustry Company Products Pipeline Risks/Catalysts Valuation Q&A. Agenda
Industry Company Products Pipeline Risks/Catalysts Valuation Q&A Agenda 1 Pharmaceutical/Biotech Pharmaceutical companies Simple molecules made by chemical process taken orally Biotech companies Complicated
More informationAstraZeneca enhances long-term growth through Oncology investment in Acerta Pharma
AstraZeneca enhances long-term growth through Oncology investment in Acerta Pharma PUBLISHED17 December 2015Transaction includes late-stage, potential best-in-class irreversible small molecule BTK inhibitor,
More informationSummary of Strategic Competitive Analysis and Publication Planning
Summary of Strategic Competitive Analysis and Publication Planning Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Briefing
More informationCHAPTER ONE: EXECUTIVE SUMMARY
CHAPTER ONE: EXECUTIVE SUMMARY Introduction Scope and Methodology Total Size and Growth of the Market Issues and Trends Affecting Market Leading Competitors CHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDS
More informationCANCER 1.7 M 609,000 26% 15.5 M 73% JUST THE FACTS. More Than 1,100 Cancer Treatments in Clinical Testing Offer Hope to Patients
CANCER MEDICINES IN DEVELOPMENT 2018 REPORT JUST THE FACTS MORE THAN 1.7 M ESTIMATED NEW CASES OF CANCER IN 2018 IN THE UNITED STATES MORE THAN 609,000 U.S. CANCER DEATHS ARE EXPECTED IN 2018 SINCE PEAKING
More informationDealdoc. Licensing, development and marketing agreement for Relenza. Glaxo Wellcome GlaxoSmithKline Biota. Sep
Dealdoc Licensing, development and marketing agreement for Relenza Glaxo Wellcome GlaxoSmithKline Biota Sep 04 2000 Licensing, development and marketing agreement for Relenza Glaxo Wellcome Companies:
More informationREFERENCE CODE GDHC282DFR PUBLICATION DATE OCTOBER 2013 BELVIQ (OBESITY) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC282DFR PUBLICATION DATE OCTOBER 2013 BELVIQ (OBESITY) - Executive Summary Below table provides a summary of Belviq for obesity in the nine major pharmaceutical markets during the forecast
More informationMerriman Investment Summit 2009
Merriman Investment Summit 2009 10 November 2009 Robert Klupacs, CEO & Managing Director Circadian Technologies (ASX.CIR) Disclaimer Investment in Circadian Technologies Limited ( Circadian ) is subject
More informationAVENUE THERAPEUTICS, INC. NASDAQ: ATXI JANUARY 2018
AVENUE THERAPEUTICS, INC. NASDAQ: ATXI JANUARY 2018 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward-looking statements within the meaning
More informationMerrill Lynch Global Healthcare Conference February 4, Shire Pharmaceuticals Group plc
Merrill Lynch Global Healthcare Conference February 4, 2003 Shire Pharmaceuticals Group plc Comment on the Safe Harbor Statement under the Private Securities Litigation Reform Act of 995 The statements
More informationChronic illness is a growing market for Novo Nordisk
Chronic illness is a growing market for Novo Nordisk Aslam Dalvi - Associate Portfolio Manager Denmark-based global healthcare company Novo Nordisk traces its origins to the first pioneers in insulin production
More informationDo Firms Underinvest In Long-Term Research? Evidence From Cancer Clinical Trials
SIEPR policy brief Stanford University May 2014 Stanford Institute for Economic Policy Research on the web: http://siepr.stanford.edu Do Firms Underinvest In Long-Term Research? Evidence From Cancer Clinical
More information(212) Investors Contact: Ryan Crowe (212)
For immediate release: February 5, 2014 Media Contact: Sally Beatty (212) 733-6566 Investors Contact: Ryan Crowe (212) 733-8160 Pfizer And Merck To Collaborate On Innovative Anti-Cancer Combination Studies
More informationNovartis AG (NYSE: NVS) Disston Moore and Scott Schimmel. November 15, Company Profile:
Novartis AG (NYSE: NVS) Disston Moore and Scott Schimmel November 15, 2009 Company Profile: Novartis AG, through its subsidiaries, engages in the research, development, manufacture, and marketing of healthcare
More information